Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy

National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B

(2013) Michael F. Sorrell   ANNALS OF INTERNAL MEDICINE

Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA

(2009) Jung Im Seok et al.   HEPATOLOGY

Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B

(2009) Holger G. Hass et al.   JOURNAL OF GASTROENTEROLOGY

Clevudine myopathy in patients with chronic hepatitis B

(2009) Byung Kook Kim et al.   JOURNAL OF HEPATOLOGY

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B

(2009) Russell D. Fleischer et al.   JOURNAL OF HEPATOLOGY

Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

(2009) Stefan Zeuzem et al.   JOURNAL OF HEPATOLOGY

Review article: current antiviral therapy of chronic hepatitis B

(2008) W. S. AYOUB et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Current antiviral therapies for chronic hepatitis B

(2008) Mari Inada et al.   HEPATOLOGY RESEARCH